Published in Health Aff (Millwood) on March 08, 2006
Dual eligibles with mental disorders and Medicare part D: how are they faring? Health Aff (Millwood) (2009) 1.11
The effect of depression and cognitive impairment on enrollment in Medicare Part D. J Am Geriatr Soc (2009) 0.90
Trends in out-of-pocket medical care expenditures for Medicare-age adults with arthritis between 1998 and 2004. Arthritis Rheum (2008) 0.89
Prescription drug use and expenditures among dually eligible beneficiaries. Health Care Financ Rev (2007) 0.85
Estimating causal effects in observational studies using Electronic Health Data: Challenges and (some) solutions. EGEMS (Wash DC) (2013) 0.80
Changes in drug coverage generosity and untreated serious mental illness: transitioning from Medicaid to Medicare Part D. JAMA Psychiatry (2015) 0.79
Differences in the Treatment of Benign Prostatic Hyperplasia: Comparing the Primary Care Physician and the Urologist. Urol Pract (2017) 0.75
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics (2010) 1.55
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis (2011) 1.19
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics (2002) 1.06
The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. Value Health (2003) 1.01
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics (2006) 0.99
Potential cost-effectiveness of universal access to modern contraceptives in Uganda. PLoS One (2012) 0.98
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care (2011) 0.97
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials (2012) 0.97
Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res (2013) 0.96
Economic incentives for evidence generation: promoting an efficient path to personalized medicine. Value Health (2013) 0.92
Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. Am J Manag Care (2006) 0.90
Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ (2012) 0.89
Preference values associated with stage III colon cancer and adjuvant chemotherapy. Qual Life Res (2010) 0.89
Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. J Infect Dis (2011) 0.89
Paying for outcomes: innovative coverage and reimbursement schemes for pharmaceuticals. J Manag Care Pharm (2009) 0.87
Examining the BMI-mortality relationship using fractional polynomials. BMC Med Res Methodol (2011) 0.87
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin (2011) 0.86
Systematic review of comparative effectiveness data for oncology orphan drugs. Am J Manag Care (2012) 0.86
Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity. Eur J Health Econ (2013) 0.84
Editorial: On the benefits of modeling using QALYs for societal resource allocation: the model is the message. Value Health (2009) 0.83
Universal health coverage--big thinking versus big data. Value Health (2012) 0.82
The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature. Expert Rev Pharmacoecon Outcomes Res (2012) 0.81
Comparative-effectiveness research to aid population decision making by relating clinical outcomes and quality-adjusted life years. Clin Ther (2013) 0.81
Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer. Expert Rev Pharmacoecon Outcomes Res (2010) 0.81
BMI trajectories among the severely obese: results from an electronic medical record population. Obesity (Silver Spring) (2012) 0.80
A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries. Drug Saf (2014) 0.80
A review of data needed to parameterize a dynamic model of measles in developing countries. BMC Res Notes (2010) 0.80
Paying for personalized care: cancer biomarkers and comparative effectiveness. Mol Oncol (2012) 0.80
The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. J Med Econ (2010) 0.80
Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. J Cancer Res Clin Oncol (2009) 0.79
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin (2011) 0.79
Patient characteristics and medical care costs associated with hypertriglyceridemia. Am J Cardiol (2011) 0.78
Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States. J Med Econ (2012) 0.78
Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ (2011) 0.77
Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy. Genet Med (2012) 0.77
Assessment of the effectiveness of supply-side cost-containment measures. Health Care Financ Rev (1992) 0.77
Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Rev Anti Infect Ther (2010) 0.77
Retrospective outcomes studies for orphan diseases: challenges and opportunities. Curr Med Res Opin (2012) 0.77
Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US. J Med Econ (2014) 0.76
Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies. Pharmacoepidemiol Drug Saf (2014) 0.76
Authors' reply to Curto and Garattini: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers". Appl Health Econ Health Policy (2014) 0.75
Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). J Manag Care Spec Pharm (2015) 0.75
Apples and Oranges? Assessing Comparative Effectiveness and Comparative Value in the US and Other Countries. Value Health (2010) 0.75
Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. Value Health (2013) 0.75